-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-05-14
Values as of: 2024-05-14
Currency: AUD
Country : Australia
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
CBAPI:AU | Commonwealth Bank of Australia.. |
N/A |
USD 191.08B |
CBAPG:AU | Commonwealth Bank of Australia.. |
N/A |
USD 177.78B |
CGFPC:AU | Challenger Ltd Preferred |
N/A |
USD 4.44B |
MGF:AU | Magellan Global Fund Unit |
N/A |
USD 2.85B |
LSF:AU | L1 Long Short Fund Ltd |
+0.01 (+0.32%) |
USD 1.90B |
ASK:AU | ABACUS STORAGE KING |
N/A |
USD 1.59B |
VG1:AU | VGI Partners Global Investment.. |
+0.01 (+0.26%) |
USD 0.77B |
KKC:AU | Kkr Credit Income Fund |
-0.02 (-0.86%) |
USD 0.73B |
RF1:AU | Regal Investment Fund |
-0.08 (-2.42%) |
USD 0.54B |
PCI:AU | Perpetual Credit Income Trust |
-0.01 (-0.45%) |
USD 0.43B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
SUBD:AU | VanEck Australian Subordi.. | 5.49 % | 0.00 % |
N/A |
USD 1.38B |
GERM | ETFMG Treatments Testing .. | 5.30 % | 0.00 % |
-0.15 (0.17%) |
USD 0.01B |
US3:PA | 4.97 % | 0.00 % |
N/A |
N/A | |
PTH | Invesco DWA Healthcare Mo.. | 2.66 % | 0.60 % |
-0.22 (0.17%) |
USD 0.14B |
US1:PA | 2.18 % | 0.00 % |
N/A |
N/A | |
CNCR | Loncar Cancer Immunothera.. | 1.88 % | 0.79 % |
-0.21 (0.17%) |
USD 0.02B |
FLOT:AU | VanEck Australian Floatin.. | 1.82 % | 0.00 % |
N/A |
USD 0.69B |
UEFZ:F | UBS ETF SICAV - SBI Forei.. | 1.53 % | 0.00 % |
+0.01 (+0.17%) |
USD 0.40B |
UEFZ:XETRA | UBS - SBI Foreign AAA-BBB.. | 1.53 % | 0.00 % |
+0.02 (+0.17%) |
USD 0.42B |
F5ESG:SW | UBS(Lux)Fund Solutions .. | 1.53 % | 0.00 % |
+0.02 (+0.17%) |
USD 0.40B |
FYC | First Trust Small Cap Gro.. | 0.82 % | 0.70 % |
-0.14 (0.17%) |
USD 0.27B |
FYX | First Trust Small Cap Cor.. | 0.41 % | 0.63 % |
-0.46 (0.17%) |
USD 0.86B |
XCCC | BondBloxx ETF Trust | 0.05 % | 0.00 % |
-0.18 (0.17%) |
USD 0.06B |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
The company had negative total cash flow in the most recent four quarters.